GMED — Globus Medical, Inc. stock price, charts and financials

QT61Globus Medical, Inc.

Globus Medical, Inc. (NYSE: GMED) is a Healthcare company in the Medical - Devices industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
81.46
+2.67+3.39%
GMEDQT61Globus Medical, Inc.·NYSE
81.46+3.39%
Analyst
Up 3.4% — UBS initiated coverage at Neutral, price target $82.
Medium confidence
TA
Loading chart...
Screen all →
Snapshot
Index-P/E18.11EPS (ttm)4.35Insider Own17.54%Shs Outstand134.86MPerf Week3.01%
Market Cap10.63BForward P/E15.32EPS next Y5.14Insider Trans-0.23%Shs Float133.90MPerf Month3.73%
Enterprise Value10.18BPEG0.08EPS next Q-Inst Own-Short Float5.28%Perf Quarter-12.63%
Income584.43MP/S3.43EPS this Y10.73%Inst Trans-Short Ratio4.02Perf Half Y-12.67%
Sales3.10BP/B2.25EPS next Y8.54%ROA10.79%Short Interest7.07MPerf YTD-9.76%
Book/sh-P/C13.70EPS next 5Y12.01%ROE13.04%52W High104.84 -22.30%Perf Year47.41%
Cash/sh-P/FCF17.70EPS past 3/5Y28.44% 31.16%ROIC9.72%52W Low53.55 52.13%Perf 3Y26.57%
Dividend Est.-EV/EBITDA11.57Sales past 3/5Y42.16% 30.08%Gross Margin67.86%Volatility3.27% 3.57%Perf 5Y-5.12%
Dividend TTM-EV/Sales3.28EPS Y/Y TTM470.67%Oper. Margin17.62%ATR (14)2.85Perf 10Y203.16%
Dividend Ex-Date-Quick Ratio2.95Sales Y/Y TTM23.06%Profit Margin18.92%RSI (14)49.84Recom2.31
Dividend Gr. 3/5Y-Current Ratio4.56EPS Q/Q64.71%SMA200.94%Beta0.94Target Price98.88
Payout0.00%Debt/Eq0.02Sales Q/Q27.09%SMA50-1.16%Rel Volume0.57Prev Close78.79
Employees6,000LT Debt/Eq0.02EarningsAug 06SMA200-6.14%Avg Volume1.86MPrice81.46
IPO DateAug 03, 2012Option/ShortYes / YesEPS/Sales Surpr.21.80% 2.63%Net Debt/EBITDA-0.51Volume1,054,232Change3.39%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-28-26InitiatedUBSNeutral$82
Jul-16-26ReiteratedTruist SecuritiesBuy$115$100
Jul-13-26ReiteratedRBC CapitalOutperform$100$115
Jul-08-26InitiatedBMO CapitalOutperform$94
Jul-08-26ReiteratedStifel Nicolaus$64$80
Jun-15-26ReiteratedPiper SandlerOverweight$115$100
May-08-26ReiteratedNeedhamBuy$112$117
May-08-26ReiteratedWells FargoOverweight$78$103
Feb-25-26ReiteratedTruist FinancialBuy$105$115
Jan-30-26UpgradeNeedhamHoldBuy$71$112
Latest News
Jul-31-26
Jul-28-26
Jul-27-26
Jul-24-26
Jul-23-26
Jul-22-26
Jul-20-26
Jul-17-26
Jul-16-26
Jul-15-26
Jul-08-26
Company

Globus Medical, Inc. is a global medical technology company dedicated to inventing, developing, and marketing a diverse range of healthcare solutions. Their primary focus is on addressing musculoskeletal disorders for patients worldwide. Their extensive portfolio includes a variety of spinal products. These encompass traditional fusion implants like pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices, all designed to treat conditions such as degenerative diseases, deformities, tumors, and trauma. Furthermore, they offer advanced motion preservation technologies, including dynamic stabilization, total disc replacement, and interspinous distraction devices. The company also provides interventional pain management options for vertebral compression fractures, alongside a selection of regenerative biologic products such as allografts and synthetic alternatives. Beyond spinal care, Globus Medical manufactures solutions for orthopedic trauma, featuring products like fracture plates, compression screws, intramedullary nails, and external fixation systems. They also specialize in hip and knee joint reconstruction, offering modular hip stems, acetabular cups, and various knee arthroplasty implants, including posterior stabilizing and cruciate retaining designs. Additionally, the company engages in the distribution of human cell, tissue, and other cellular and tissue-based products. Established in 2003, Globus Medical, Inc. maintains its corporate headquarters in Audubon, Pennsylvania.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue3,1002,9392,5191,5681,023958789785713
Cost of Goods Sold Incl. D&A9969581,035548264239217180159
Gross Profit2,1051,9811,4841,020759719572605554
Selling, General and Administrative Excl. Other1,3721,316981643432408355355312
Research and Development1891851641247397856055
Other Operating Expense-201731202642201817
Operating Income547480166133228172111172169
Interest Expense004000000
Unusual Expense
Non-Operating Income (Expense)117130-4132158141819
Net Income Before Taxes663610121165243180126190189
Income Taxes767218435331243532
Consolidated Net Income587538103123190149102155156
Net Income From Continuing Operations587538103123190149102155156
Net Income587538103123190149102155156
EPS (Recurring)4.353.980.761.091.891.481.041.571.60
EPS (Basic, Before Extraordinaries)4.353.980.761.091.891.481.041.571.60
EPS (Diluted)4.283.920.751.071.851.441.011.521.54
EBITDA879730474347305265178229219
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio19.0322.27110.2849.8040.1550.1464.5738.7428.10
Price To Sales Ratio3.554.014.473.847.267.618.187.435.95
Gross Margin67.9067.4058.9165.0574.1975.0572.5077.0777.70
Operating Margin17.6516.336.598.4822.2917.9514.0721.9123.70
Net Margin18.9418.314.097.8418.5715.5512.9319.7521.88
Shares Outstanding135135136113100101999998
Market Capitalization10,99711,78711,2496,0227,4277,2926,4575,8294,241
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$103.56$88.96$74.35$59.75$45.15 Close Price0.00M1.44M2.88M4.31M5.75MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Davidar David DDirectorJun 05 '26Sale80.7625,0002,019,073510,175Jun 09
Davidar David DDirectorJun 05 '26Option Exercise26.2725,000656,750535,175Jun 09
RHOADS ANN DDirectorJun 04 '26Option Exercise26.2725,000656,75040,384Jun 08
Huller KellyEVP, GC, Corporate SecretaryFeb 25 '26Sale94.5020,0001,890,0000Feb 27
Huller KellyEVP, GC, Corporate SecretaryFeb 25 '26Option Exercise43.5820,000871,60020,000Feb 27
Huller KellyEVP, GC, Corporate SecretaryFeb 12 '26Option Exercise45.6410,000456,40010,000Feb 17
Huller KellyEVP, GC, Corporate SecretaryFeb 12 '26Sale87.6710,000876,7000Feb 17
Kline KyleSenior Vice President, CFOJan 08 '26Sale101.103,594363,3530Jan 12
Norwalk Leslie VDirectorJan 08 '26Sale101.102,000202,20010,419Jan 12
Kline KyleSenior Vice President, CFOJan 08 '26Option Exercise51.873,594186,4213,594Jan 12
Norwalk Leslie VDirectorDec 12 '25Sale88.854,000355,40012,419Dec 16
Paul David CExecutive ChairmanDec 08 '25Option Exercise25.5234,375877,25060,417Dec 10
Kline KyleSenior Vice President, CFODec 01 '25Sale90.0018,5421,668,7800Dec 03
Kline KyleSenior Vice President, CFODec 01 '25Option Exercise59.8618,5421,109,87518,542Dec 03
Huller KellySVP, GC, Corporate SecretaryNov 25 '25Option Exercise25.967,500194,7007,500Nov 28
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.